{"status":"success","_timestamp":1.7426621201110961e+09,"_runtime":0.601403,"_step":0,"_wandb":{"runtime":0},"study_name":"Study from Banna 2022.pdf","extracted_data":{"file_name":"Banna 2022.pdf","raw_data":{"countries":["United Kingdom","Switzerland"],"populations":[{"stage_histology":"Stage IIIB/IVA, adenocarcinoma","pdl1_status":"PD-L1 negative","n":164},{"stage_histology":"Stage IVB, adenocarcinoma","pdl1_status":"PD-L1 negative","n":171},{"pdl1_status":"PD-L1 positive","n":51,"stage_histology":"Stage IIIB/IVA, squamous"}],"results":{"median_pfs":"8.0 months","os_12_month":"52.2%","treatment_specific_results":{"first-line chemoimmunotherapy":{"median_pfs":"8.0 months","median_os":"12.7 months"}},"group_difference":"p D0.001","median_os":"12.7 months","median_rw_pfs":"8.0 months"},"treatment_regimens":["first-line chemoimmunotherapy","pembrolizumab plus platinum-based chemotherapy"]},"study_name":"Study from Banna 2022.pdf"}}